<DOC>
	<DOCNO>NCT00244946</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carmustine , etoposide , cytarabine , melphalan work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy . Giving white blood cell , treat laboratory antibody , may make transplant work well . Giving combination chemotherapy follow autologous stem cell transplant , white blood cell infusion may effective treatment non-Hodgkin 's lymphoma . PURPOSE : This phase I trial study side effect best dose white blood cell infusion give together combination chemotherapy , autologous stem cell transplant treat patient non-Hodgkin 's lymphoma relapse , refractory , remission .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Autologous Stem Cell Transplant , White Blood Cell Infusions Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity high-dose combination chemotherapy comprise cyclophosphamide , thiotepa , carboplatin follow autologous peripheral blood stem cell transplantation immunotherapy consolidation therapy comprise anti-CD3 x anti-CD20 bispecific antibody ( CD20Bi ) -activated T cell ( ATC ) patient non-Hodgkin 's lymphoma . - Determine maximum tolerate dose CD20Bi-ATC patient treat regimen . - Determine whether ATC traffic tumor site select patient treated regimen . - Assess immune reconstitution B cell incidence infection patient treat regimen . - Compare relapse rate overall survival patient treat regimen historical control . OUTLINE : This dose-escalation study activate T cell . - Peripheral blood stem cell ( PBSC ) mobilization collection : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 5 day . They undergo leukaphereses collect peripheral blood stem cell ( PBSC ) . Some lymphocyte treat laboratory produce anti-CD3 x anti-CD20 bispecific antibody ( CD20Bi ) -activated T cell ( ATC ) . - High-dose chemotherapy PBSC transplantation : Patients receive carmustine IV day -7 , etoposide IV twice daily cytarabine IV twice daily day -6 , -5 , -4 , -3 , melphalan IV day -2 . Autologous PBSC reinfused day 0 . - Immunotherapy consolidation : Patients receive immunotherapy consolidation comprise CD20Bi-ATC IV 15-30 minute start day 4 , week 4 week total four infusion . Cohorts 3-6 patient receive escalate dos CD20Bi-ATC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 12-24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20+ nonHodgkin 's lymphoma Disease refractory , relapse , remission Measurable evaluable disease PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Hemoglobin &gt; 8 g/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 50,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL SGOT SGPT ≤ 2.5 time normal No history severe hepatic dysfunction Renal Creatinine ≤ 2.0 mg/dL OR Creatinine clearance ≥ 60 mL/min No uncompensated major adrenal dysfunction BUN &lt; 1.5 time normal Cardiovascular No severe cardiac dysfunction No major heart disease LVEF ≥ 50 % MUGA No uncontrolled hypertension No congenital acquire heart disease cardiac arrhythmia unless cardiac consult evaluation do Pulmonary DLCO ≥ 50 % normal No symptomatic obstructive restrictive disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection HIV negative No significant skin breakdown tumor disease Dental evaluation teeth clean potential source infection require No uncompensated major thyroid dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy No prior stem cell transplantation Chemotherapy No prior total doxorubicin daunorubicin dose ≥ 450 mg/m^2 unless endomyocardial biopsy show &lt; grade 2 drug effect AND ejection fraction ≥ 50 % gate blood pool scan Endocrine therapy No concurrent hormonal therapy except steroid adrenal failure , septic shock , pulmonary toxicity hormone nondiseaserelated condition ( e.g. , insulin diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
</DOC>